Breakfast Technical Briefing on Generic Drugs Stocks -- Mallinckrodt, Akorn, Pacira Pharma, and Rigel Pharma

Friday, November 10, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 10, 2017 /PRNewswire/ --

If you want a Stock Review on MNK, AKRX, PCRX, or RIGL then come over to

http://dailystocktracker.com/register/ and sign up for your free customized report. Generic Drugs manufacturers are a compelling investment theme for investors. There are a number of other trends in the industry - from aging populations and higher
healthcare spending to mergers and acquisitions - that could make it even more attractive. This morning, DailyStockTracker.com takes a closer look at four equities in this space to see how they have fared over the past trading sessions: Mallinckrodt PLC (NYSE: MNK), Akorn Inc. (NASDAQ: AKRX), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and Rigel Pharmaceuticals Inc. (NASDAQ: RIGL). Daily Stock Tracker published free research reports on these stocks today at: http://dailystocktracker.com/register/

Mallinckrodt

Staines-Upon-Thames, the UK headquartered Mallinckrodt PLC's shares jumped 11.11%, closing Thursday's trading session at $22.20. The stock recorded a trading volume of 8.87 million shares, which was above its three months average volume of 2.83 million shares. The Company's shares are trading 34.63% below their 50-day moving average. Additionally, shares of Mallinckrodt, which develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the US, Europe, Middle-East, Africa, and internationally, have a Relative Strength Index (RSI) of 26.40. 

On November 02nd, 2017, Mallinckrodt (MNK) and Ocera Therapeutics, Inc. (OCRX) announced that they have entered into an agreement under which MNK will acquire OCRX, a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for orphan and other serious liver diseases with high unmet medical need. Ocera's developmental product OCR-002, an ammonia scavenger, is being studied for treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia, which is a complication of acute or chronic liver disease.

On November 08th, 2017, research firm Canaccord Genuity reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $38 a share to $24 a share. See our free and comprehensive research report on MNK at: http://dailystocktracker.com/registration/?symbol=MNK

Akorn

On Thursday, shares in Lake Forest, Illinois headquartered Akorn Inc. recorded a trading volume of 2.41 million shares. The stock declined 0.27%, ending the day at $33.15. The Company's shares have advanced 0.61% in the past month and 51.86% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.34% and 9.19%, respectively. Furthermore, shares of Akorn, which develops, manufactures, and markets specialized generic and branded pharmaceuticals, over-the-counter (OTC) drug products, and animal health products in the US and internationally, have an RSI of 53.06.  AKRX free research report is just a click away at: http://dailystocktracker.com/registration/?symbol=AKRX

Pacira Pharmaceuticals

Parsippany, New Jersey headquartered Pacira Pharmaceuticals Inc.'s stock finished the day 2.07% lower at $40.15. A total volume of 976,541 shares was traded, which was above their three months average volume of 673,320 shares. The Company's shares have advanced 16.72% in the last one month, 10.30% in the previous three months, and 24.30% on an YTD basis. The stock is trading above its 50-day moving average by 12.09%. Additionally, shares of Pacira Pharma have an RSI of 66.45. 

On October 25th, 2017, Pacira Pharma announced that it has committed to invest up to $25 million in TELA Bio, a privately-held surgical reconstruction company that markets its proprietary OviTex™ portfolio of products for ventral hernia repair and abdominal wall reconstruction. TELA Bio's OviTex Reinforced BioScaffold products are a distinct class of surgical implants that integrate biologic and synthetic materials in a unique embroidered construction that allows free movement of fluid and cells through the construct.

On November 09th, 2017, research firm H.C. Wainwright resumed its 'Buy' rating on the Company's stock, with a target price of $52 per share. Sign up for your complimentary report on PCRX at: http://dailystocktracker.com/registration/?symbol=PCRX

Rigel Pharmaceuticals

Shares in South San Francisco, California-based Rigel Pharmaceuticals Inc. ended yesterday's session 2.35% lower at $3.74. The stock recorded a trading volume of 1.17 million shares. The Company's shares have surged 71.56% over the previous three months and 57.14% since the start of this year. The stock is trading 16.35% and 35.22% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Rigel Pharma, which engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology, have an RSI of 54.36. 

On November 02nd, 2017, Rigel Pharma announced that Gregg Lapointe, CPA, MBA has been appointed to the Company's Board of Directors. Currently the CEO and Co-founder of Cerium Pharmaceuticals, Inc., Mr. Lapointe offers the board nearly three decades of commercial and financial experience, bringing products to market in the areas of medical devices and rare diseases. 

On November 06th, 2017, research firm H.C. Wainwright resumed its 'Buy' rating on the Company's stock, with a target price of $7 per share. Register for free on DailyStockTracker.com and download the latest research report on RIGL at: http://dailystocktracker.com/registration/?symbol=RIGL

--

Daily Stock Tracker:

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]Phone number: (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

 

View original content:http://www.prnewswire.com/news-releases/breakfast-technical-briefing-on-generic-drugs-stocks----mallinckrodt-akorn-pacira-pharma-and-rigel-pharma-300553723.html

SOURCE dailystocktracker.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store